Wang, S.-J.S.-J.WangYUNG-TE HOULIN-CHI CHEN2018-09-102018-09-102015http://www.scopus.com/inward/record.url?eid=2-s2.0-84938917594&partnerID=MN8TOARShttp://scholars.lib.ntu.edu.tw/handle/123456789/390456A novel selective decoy oligodeoxynucleotide (dODN)-doxorubicin (DOX) complex is reported for cancer theranostics. It eliminates the use of a ligand or carrier for targeted delivery and disassembles into therapeutic dODN and DOX upon encountering over-activated STAT3 in cancer cells. Hence, in situ STAT3 probing and synergistic anti-cancer effect are attained at the same time. ? 2015 Royal Society of Chemistry.[SDGs]SDG3aptamer; bovine serum albumin; doxorubicin; lipofectamine; oligodeoxynucleotide; quantum dot; STAT3 protein; streptavidin; antineoplastic agent; doxorubicin; drug carrier; fluorescent dye; lipid; oligodeoxyribonucleotide; STAT3 protein; STAT3 protein, human; antineoplastic activity; apoptosis; Article; binding affinity; binding competition; cancer cell; cell death; circular dichroism; competitive binding assay; drug potentiation; drug release; fluorescence microscopy; liposomal delivery; malignant neoplastic disease; MCF 7 cell line; protein binding; ultraviolet spectroscopy; antagonists and inhibitors; chemistry; HepG2 cell line; human; theranostic nanomedicine; Antineoplastic Agents; Doxorubicin; Drug Carriers; Fluorescent Dyes; Hep G2 Cells; Humans; Lipids; MCF-7 Cells; Oligodeoxyribonucleotides; STAT3 Transcription Factor; Theranostic Nanomedicinejournal article10.1039/c5cc04435a